We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 144

In Uship Federal Circuit finds prosecution history disclaimer in arguments against restriction requirement

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • May 23 2013

In Uship Intellectual Properties, LLC v. United States, the Federal Circuit upheld the claim construction applied by the Court of Federal Claims when

Supreme Court finds for Monsanto in seed harvesting case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • May 16 2013

In Bowman v. Monsanto Co., the Supreme Court held that the doctrine of patent exhaustion does not give a farmer who has bought patented seeds the

Federal Circuit issues fractured affirmance in CLS Bank v. Alice Corporation

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • May 12 2013

In a fractured en banc decision, the Federal Circuit affirmed the district court's holding that the claims at issue in CLS Bank v. Alice Corporation

Federal Circuit upholds one claim covering Combigan

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • May 7 2013

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit reversed the district court in part, finding that Allergan's composition claims and most of

Federal Circuit holds that patent indefiniteness requires insoluble ambiguousness

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • May 2 2013

In Biosig Instruments, Inc. v. Nautilus Inc., the Federal Circuit reversed the district court's finding that the claims at issue were invalid as

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Federal Circuit finds Yaz patent obvious

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 25 2013

In Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court and held that Bayer's

Challenging the enabling quality of Prior Art

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 18 2013

In In re Morsa, the Federal Circuit reversed an anticipation rejection where the applicant had challenged the enabling quality of the cited prior art

Supreme Court hears oral arguments in "ACLUMyriad" gene patenting case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 15 2013

On April 15, 2013, the Supreme Court heard oral arguments in one of the most controversial and publicized biotech patent cases, the "ACLUMyriad"

Supreme Court oral arguments in ACLU Myriad gene patent case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 15 2013

On April 15, 2013, the Supreme Court heard oral arguments in one of the most controversial and publicized biotech patent cases-the "ACLUMyriad" gene